MMP2 SERUM LEVELS

CI-VAR-00004154Explore in graph →CIViC 487

Curated evidence

Evidence by cancer (2 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–2 of 2 evidence items across 2 cancer contexts on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Breast Inflammatory Carcinoma1
MMP2 SERUM LEVELS	Bevacizumab	Predictive	B	Supports Sensitivity Response	3	accepted	EID1156 MMP2 serum levels were assessed (ELISA) at baseline (b) and before surgery in 45 available samples from patients with inflammatory breast cancer treated with bevacizumab-based neoadjuvant therapy. Hig… (full text at CIViC) PMID 26921265 · Tabouret et al., 2016 · Open in CIViC	civic
Brain Glioma1unmapped disease
MMP2 SERUM LEVELS	Bevacizumab	Predictive	B	Supports Sensitivity Response	2	accepted	EID1158 Plasma levels of 11 potential biomarkers were tested at baseline and 2 weeks after bevacizumab initiation in a prospective cohort of 26 patients with recurrent high-grade gliomas. Results were validat… (full text at CIViC)

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.